LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option TOKYO and CAMBRIDGE, Mass., Jan. 13, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and...
Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease )
Also on site :
- Ukraine doing West’s ‘dirty work’ in Africa – Sudanese official
- 'He knows where to find me,' Newsom responds to Trump administration arrest threat
- Two people killed by falling trees and thousands without power after storms sweep southern states